Ulmer & Berne’s life sciences practice is broad both in its scope and breadth. It provides representation to national and international clients on a nationwide basis and covers numerous areas of law. Our life sciences practice has an established national presence defending companies in matters that are complex both legally and scientifically. The group defends companies in class action lawsuits, consolidated state proceedings, and federal multidistrict litigation, as well as individual lawsuits.
Often, cases being handled by the life sciences group appear on the front pages of our newspapers, as well as the nightly news. Currently, the group represents clients in, among others, litigation involving OxyContin, ephedra, hormone replacement therapy, antidepressants, oral contraceptives, phenylpropanolamine (PPA), phen-fen, amiodarone, latex gloves and catheters. In some of those cases, the group defends clients against sensational stories of homicide or suicide supposedly associated with the clients’ products.
The group serves as national counsel for numerous public and private companies in the pharmaceutical, medical device and dietary supplement industries, and acts as regional counsel for a variety of others. Current representation includes several class actions, federal multidistrict litigations, state-consolidated proceedings and a wide variety of individual high-exposure lawsuits. In addition, the group serves as exclusive national product liability counsel for some of those companies.
We believe that we offer unique, high-value legal services to the pharmaceutical industry. Our group includes various areas of expertise in addition to legal. For example, members of our group have backgrounds in the disciplines of pharmacy, pharmacology, chemistry, biochemistry, medical technology, as well as business, negotiations and engineering. In addition to providing litigation defense, we perform risk assessment, due diligence for product acquisitions and mergers, advice and counsel relating to regulatory matters, and assistance in acquiring or reducing premiums for product liability insurance. We maintain a fully searchable database of every adverse event reported to the Food and Drug Administration since 1969 for every pharmaceutical product sold in the United States, which permits the compilation of statistics vital to those areas of representation.
Our life sciences practice also includes representation of companies on intellectual property law (including copyright, trademark, patent and trade secret prosecution and litigation), bioscience law, and the laws applicable to the acquisition, licensing, distribution, transfer and disposition of technology and pharmaceutical products.
Ulmer is ranked in 39 categories in the 2017 U.S. News – Best Lawyers “Best Law Firms” rankings. Among these, the firm earns U.S. News – Best Lawyers highest rankings in 21 categories. The firm also ranks nationally in 15 categories. Firms included in the 2017 “Best Law Firms” are...
November 01, 2016
Ulmer & Berne LLP announces that four of the firm’s attorneys have been recognized in the 2015 edition of Benchmark Litigation as “State Litigation Stars.” The following Ulmer & Berne attorneys were selected in their jurisdictions: Frances Floriano Goins – State Litigation Star-Cleveland Jeffrey F. Peck – State Litigation Star-Cincinnati...
September 17, 2014
Ulmer & Berne LLP has been ranked within the top 10 percent of all law firms by The BTI Consulting Group, one of the nation’s leading legal industry research firms, in their recently published 2015 BTI Litigation Outlook report. The firm was selected as a “Litigation Powerhouse” and is named...
October 23, 2014